Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIDE-Lung02: rilvegostomig vs pembrolizumab plus chemotherapy in first-line metastatic squamous NSCLC
jRCT2051240197Phase 3Recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial in non-small cell lung cancer (NSCLC) comparing rilvegostomig plus chemotherapy with pembrolizumab (Keytruda) plus chemotherapy (2 arms). Primary endpoints: Overall survival and Progression-free survival. Started Dec 2024; status: recruiting.
02
Drugs
rilvegostomigpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051240197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240197.